CAC2 Childhood Cancer Community News Digest (May 27-June 2)

Assorted News from the Last Week:

The FDA granted accelerated approval to Eli Lilly And Co’s selpercatinib (Retevmo) for pediatric patients two years of age and older with the following:

  • Advanced or metastatic medullary thyroid cancer (MTC) with a RETmutation, who require systemic therapy.
  • Advanced or metastatic thyroid cancer with a RET gene fusion, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
  • Locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.

Three blog posts by CAC2 Members:

Researchers have demonstrated that some childhood leukemia originate during embryonic development, although they do not manifest after a few months after birth.

High-deductible health plans appeared associated with shorter survival among cancer survivors.

NCI take on tovorafenib (Ojemda) for some children with low grade gliomas.

Preventing sepsis during treatment for pediatric cancer might prevent neurocognitive problems decades later in survivors.

Upcoming Webinars, Online Opportunities, and Meetings:

Register for the Making It Better at the 7th Annual FACTOR Conference in June 20-22, 2024—an intimate gathering shaping the future of osteosarcoma care. Connect with more than 60 dedicated doctors and researchers, resilient patients and families, and insightful scientific panels in thoughtful discussions, shared experiences, with a touch of fun.  For information and to register.

Join Camp Erin for a two-day photography virtual event to explore the use of photography as a unique form of grief expression. Attendees will learn basic photography skills and incorporate the use of imagery in expressing thoughts and feelings difficult to share in words. This online event will serve teens and young adults grieving the death of a significant person in their lives.  Evenings on June 22 and June 29. For information and to register.

Triage Cancer is presenting a webinar for caregivers on June 27, 2024 at 1:00 ET.  Learn about the rights of caregivers at work, how to replace lost wages while acting as a caregiver, and practical tips to support caregivers. We’ll also talk about community resources available to caregivers. For information and to register.

The 21st International Symposium on Pediatric Neuro-Oncology (ISPNO 2024) from June 29 – July 2, 2024, and the Annual Meeting of the Brain Tumor Group of SIOP Europe (SIOPE-BTG) from June 28-29, 2024, which will take place in Philadelphia, PA.  For information and to register.

56th Congress of the International Society of Paediatric Oncology (SIOP 2024), which will take place in Honolulu, Hawaii, USA | October 17-20, 2024. Registration is open and anyone who registers before July 17, 2024 can take advantage of the discounted rates.

Past Recordings

Watch: FDA Pediatric ODAC discussion of RACE Act

Take Action:

Try out the monthly donation platform dedicated to childhood cancer that helps nonprofits and warrior-parents team up to raise money for research, family support, and advocacy offered at no charge by Hello Cure. 

The Children’s Cancer Cause announced that the organization is accepting applications for its 2024 Survivorship Champion’s Prize. This $10,000 annual award is presented to a group, program or institution making significant advances in programs and services to provide life-long health maintenance for survivors of pediatric cancers.

Announcing a new Childhood Cancer Data Initiative (CCDI)–related Request for Proposals (RFP). The RFP invites proposals from organizations able to perform molecular profiling using specimens from children, adolescents, and young adults with cancer. Submissions will be accepted until 3:00 p.m. ET on June 14, 2024.

SUBSCRIBE

Sign up to receive a copy of CAC2's free childhood cancer news digest in your inbox each week.

Name(Required)
Email(Required)
This field is for validation purposes and should be left unchanged.